Demographic, clinical and laboratory characteristics of rapidly progressive glomerulonephritis in Turkey: Turkish Society of Nephrology-Glomerular Diseases (TSN-GOLD) Working Group
- PMID: 33040246
- DOI: 10.1007/s10157-020-01978-6
Demographic, clinical and laboratory characteristics of rapidly progressive glomerulonephritis in Turkey: Turkish Society of Nephrology-Glomerular Diseases (TSN-GOLD) Working Group
Abstract
Background: In our study, diagnostic and demographic characteristics of patients diagnosed with RPGN by biopsy, clinical and laboratory findings in our country were investigated.
Methods: Data were obtained from the Turkish Society of Nephrology Glomerular Diseases (TSN-GOLD) Working Group database. Demographic characteristics, indications for biopsy, diagnosis of the glomerular diseases, comorbidities, laboratory and biopsy findings of all patients were recorded. According to their types, RPGN patients were classified as type 1 (anti-GBM related), type 2 (immuncomplex related) and type 3 (pauci-immune).
Results: Of 3875 patients, 200 patients with RPGN (mean age 47.9 ± 16.7 years) were included in the study which constitutes 5.2% of the total glomerulonephritis database. Renal biopsy was performed in 147 (73.5%) patients due to nephritic syndrome. ANCA positivity was found in 121 (60.5%) patients. Type 1 RPGN was detected in 11 (5.5%), type 2 RPGN in 42 (21%) and type 3 RPGN in 147 (73.5%) patients. Median serum creatinine was 3.4 (1.9-5.7) mg/dl, glomerular filtration rate was 18 (10-37) ml/min/1.73m2 and proteinuria 2100 (1229-3526) mg/day. The number of crescentic glomeruli ratio was ratio 52.7%. It was observed that urea and creatinine increased and calcium and hemoglobin decreased with increasing crescentic glomerular ratio.
Conclusions: Our data are generally compatible with the literature. Advanced chronic histopathological findings were prominent in the biopsy of 21 patients. Early biopsy should be performed to confirm the diagnosis of RPGN and to avoid unnecessary intensive immunosuppressive therapy. In addition to the treatments applied, detailed data, including patient and renal survival, are needed.
Keywords: Anti-glomerular basement membrane antibody; Anti-neutrophil cytoplasmic antibody; Immune complex glomerulonephritis; Rapidly progressive glomerulonephritis.
Similar articles
-
Demographic, clinical and laboratory characteristics of adult-onset minimal change disease in Turkey: Turkish Society of Nephrology-Glomerular Diseases (TSN-GOLD) Working Group.Int Urol Nephrol. 2023 Apr;55(4):975-982. doi: 10.1007/s11255-022-03382-3. Epub 2022 Sep 30. Int Urol Nephrol. 2023. PMID: 36178610
-
Epidemiological features of primary glomerular disease in Turkey: a multicenter study by the Turkish Society of Nephrology Glomerular Diseases Working Group.BMC Nephrol. 2020 Nov 14;21(1):481. doi: 10.1186/s12882-020-02134-8. BMC Nephrol. 2020. PMID: 33189135 Free PMC article.
-
Correlation between Pathological Findings and the Usefulness of Clinical Guidelines for the Treatment of ANCA-Positive RPGN: A Retrospective Analysis.J Nippon Med Sch. 2018;85(5):259-264. doi: 10.1272/jnms.JNMS.2018_85-41. J Nippon Med Sch. 2018. PMID: 30464142
-
Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis.Am J Kidney Dis. 2005 Aug;46(2):253-62. doi: 10.1053/j.ajkd.2005.05.003. Am J Kidney Dis. 2005. PMID: 16112043 Review.
-
Myeloperoxidase-antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis with rheumatoid arthritis: a comparison of patients without rheumatoid arthritis.Clin Exp Nephrol. 2010 Aug;14(4):325-32. doi: 10.1007/s10157-010-0278-z. Epub 2010 Mar 26. Clin Exp Nephrol. 2010. PMID: 20339893 Review.
Cited by
-
Clinico-Pathological Outcomes of Patients With Crescentic Glomerulonephritis: A Single-Center Study.Cureus. 2023 May 9;15(5):e38777. doi: 10.7759/cureus.38777. eCollection 2023 May. Cureus. 2023. PMID: 37303404 Free PMC article.
-
Clinical and pathologic features of primary membranous nephropathy in Turkey: a multicenter study by the Turkish Society of Nephrology Glomerular Diseases Working Group.Ren Fail. 2022 Dec;44(1):1048-1059. doi: 10.1080/0886022X.2022.2079526. Ren Fail. 2022. PMID: 35786180 Free PMC article.
-
Demographic, clinical and laboratory characteristics of adult-onset minimal change disease in Turkey: Turkish Society of Nephrology-Glomerular Diseases (TSN-GOLD) Working Group.Int Urol Nephrol. 2023 Apr;55(4):975-982. doi: 10.1007/s11255-022-03382-3. Epub 2022 Sep 30. Int Urol Nephrol. 2023. PMID: 36178610
-
An update on dıagnosıs and treatment of ANCA assocıated renal vasculıtıs.Int Urol Nephrol. 2023 Nov;55(11):2817-2827. doi: 10.1007/s11255-023-03565-6. Epub 2023 Apr 3. Int Urol Nephrol. 2023. PMID: 37010734 Review.
References
-
- Greenhall GH, Salama AD. What is new in the management of rapidly progressive glomerulonephritis? Clin Kidney J. 2015;8:143–50. https://doi.org/10.1093/ckj/sfv008 . - DOI - PubMed - PMC
-
- Kantauskaite M, Laucyte-Cibulskiene A, Miglinas M. Histopathological classification-A prognostic tool for rapidly progressive glomerulonephritis. Medicina (Kaunas). 2018. https://doi.org/10.3390/medicina54020017 . - DOI
-
- Wu T, Peng J, Meng T, Liu Q, Ao X, Lin W, Yin H, Chen J, Pu J, Peng Z, Peng W, Li X, Xiao X, Zhou Q, Zhong Y, Xiao P. Clinicopathological features and prognostic analysis of 49 cases with crescentic glomerulonephritis. Exp Ther Med. 2019;18:3984–90. https://doi.org/10.3892/etm.2019.8023 . - DOI - PubMed - PMC
-
- Jennette JC, Thomas DB. Crescentic glomerulonephritis. Nephrol Dial Transplant. 2001;16:80–2. - DOI
-
- Baldwin DS, Neugarten J, Feiner HD, Gluck M, Spinowitz B. The existence of a protracted course in crescentic glomerulonephritis. Kidney Int. 1987;31:790–4. https://doi.org/10.1038/ki.1987.67 . - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources